NDA 019981 · Curium
Ultratag
Technetium Tc-99m Red Blood Cell Kit · Injection
Last checked: Nov 20, 2026Latest source record: Jun 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Jun 10, 1991
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
112
4 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 2, 2025.
INDICATIONS AND USAGE Technetium Tc 99m red blood cells are used for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 10, 1991 Original approval · Type 3 - New Dosage Form
1 products under this application
- ULTRATAG · TECHNETIUM TC-99M RED BLOOD CELL KIT N/A · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Red Blood Cell Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective75
- radioisotope scan abnormal15
- pruritus7
- urticaria6
- multiple gated acquisition scan abnormal5
- radiation overdose5
- dizziness3
- drug monitoring procedure not performed3
- dyspnoea3
- erythema3
- flushing3
- lip swelling3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 13 |
| 2009 | 15 |
| 2010 | 15 |
| 2011 | 11 |
| 2012 | 8 |
| 2013 | 6 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 8 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 21 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The Necessity of Using Heparin in the UltraTag RBC Kit When Tagging Blood for a Nuclear Medicine Study.
Pigmon SR, Weatherman KD, Brehl NC, et al. · J Nucl Med Technol 2016 · Clinical Trial
Sponsor: Curium
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.